JP Morgan Maintains Inogen Inc to Overweight with Price Target $62.00

Brokerage firm JP Morgan Maintains its rating on Inogen Inc(NASDAQ:INGN). In a research note issued to the investors, the brokerage major Raises the price-target to $62.00 per share. The shares have been rated Overweight. The rating by JP Morgan was issued on Aug 5, 2016.

In a different note, On Aug 5, 2016, Stifel Nicolaus said it Downgrades its rating on Inogen Inc. The shares have been rated ‘Hold’ by the firm. JP Morgan said it Initiates Coverage on Inogen Inc, according to a research note issued on Jul 13, 2016. The shares have been rated ‘Overweight’ by the firm.

Inogen Inc (INGN) shares turned negative on Wednesdays trading session with the shares closing down -0.59 points or -1.04% at a volume of 2,08,869. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $57.44. The peak price level was also seen at $57.44 while the days lowest was $55.2462. Finally the shares closed at $56.12. The 52-week high of the shares is $58.78 while the 52-week low is $28.814. According to the latest information available, the market cap of the company is $1,128 M.

Inogen Inc(INGN) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $54.57M. Analysts had an estimated revenue of $52.44M. Earnings per share were $0.25. Analysts had estimated an EPS of $0.20.

Several Insider Transactions has been reported to the SEC. On Jul 20, 2016, Matt Scribner (EVP, Operations) sold 4,102 shares at $50.50 per share price.Also, On Jul 20, 2016, Raymond Huggenberger (CEO) sold 20,747 shares at $50.57 per share price.On Apr 14, 2016, Brenton Taylor (EVP, Engineering) sold 6,500 shares at $48.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Inogen Inc. is a medical technology company. The Company is engaged in developing manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen. The Inogen One G3 and G2 have up to 4.5 and five hours of battery life respectively. The Company’s Inogen One G2 is effective for nocturnal use.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Inogen Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Inogen Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.